Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8
PLOS Neglected Tropical Diseases · 2023
DOI: 10.1371/journal.pntd.0011851 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Shumpei Watanabe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari, Ehime, Japan. Hauptthemen laut MEDLINE: Nipah Virus, Viral Vaccines, Henipavirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Takeda Science Foundation, Kanae Foundation for the Promotion of Medical Science.
Abstract (Originalsprache)
Nipah virus (NiV) is a highly pathogenic zoonotic virus that causes severe encephalitis and respiratory diseases and has a high mortality rate in humans (>40%). Epidemiological studies on various fruit bat species, which are natural reservoirs of the virus, have shown that NiV is widely distributed throughout Southeast Asia. Therefore, there is an urgent need to develop effective NiV vaccines. In this study, we generated recombinant vaccinia viruses expressing the NiV glycoprotein (G) or fusion (F) protein using the LC16m8 strain, and examined their antigenicity and ability to induce immunity. Neutralizing antibodies against NiV were successfully induced in hamsters inoculated with LC16m8 expressing NiV G or F, and the antibody titers were higher than those induced by other vaccinia virus vectors previously reported to prevent lethal NiV infection. These findings indicate that the LC16m8-based vaccine format has superior features as a proliferative vaccine compared with other poxvirus-based vaccines. Moreover, the data collected over the course of antibody elevation during three rounds of vaccination in hamsters provide an important basis for the clinical use of vaccinia virus-based vaccines against NiV disease. Trial Registration : NCT05398796 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari, Ehime, Japan.
- Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
- Division of Veterinary Science, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
- Australian Centre for Disease Preparedness, CSIRO, Geelong, VIC, Australia.
- Public Health Office, Health and Welfare Bureau, Sapporo Municipal Government, Sapporo, Hokkaido, Japan.
ORCID-Profile: Shumpei Watanabe
Förderung
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
Zitieren
APA
Watanabe, S., Yoshikawa, T., Kaku, Y., Kurosu, T., Fukushi, S., Sugimoto, S., Nishisaka, Y., Fuji, H., Marsh, G., Maeda, K., Ebihara, H., Morikawa, S., Shimojima, M., & Saijo, M. (2023). Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011851
Vancouver
Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S, et al. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011851
BibTeX
@article{Watanabe2023,
author = {Watanabe, Shumpei and Yoshikawa, Tomoki and Kaku, Yoshihiro and Kurosu, Takeshi and Fukushi, Shuetsu and Sugimoto, Satoko and Nishisaka, Yuki and Fuji, Hikaru and Marsh, Glenn and Maeda, Ken and Ebihara, Hideki and Morikawa, Shigeru and Shimojima, Masayuki and Saijo, Masayuki},
title = {Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8},
journal = {PLOS Neglected Tropical Diseases},
year = {2023},
doi = {10.1371/journal.pntd.0011851}
}
EUVIMED